A Phase 1 interventional study of HFA-152A propellant and HFA-134A propellant in Asthma, sponsored by GlaxoSmithKline. Completed at 3 sites in United States. Open to participants aged 18 Years to 45 Years. Per ClinicalTrials.gov, last updated 2026-08-21.
Sponsored by GlaxoSmithKline · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 262 studies in Asthma by GlaxoSmithKline — 7 open to participants now, 12 under way, 7 of them phase 3. Asthma · GlaxoSmithKline.
Among the 262 studies in Asthma by GlaxoSmithKline, this one is the 200th largest by enrollment of the 238 interventional ones that give a count, is one of 2 that started in 2025, is one of 62 in phase 1, and was the 254th registered.
4,849 studies on the registry are indexed under Asthma; 605 are open to participants now.
Browse Asthma studies →7 of the 262 studies in Asthma by GlaxoSmithKline are open now, in 12 countries. Recruiting first, the newest first:
GlaxoSmithKline · Sites in United States, Argentina, Canada and 1 more country
Ages 18+
GlaxoSmithKline · Sites in United States
Ages 12–80
GlaxoSmithKline · Sites in United States, Japan
Ages 12–80
GlaxoSmithKline · Sites in United States
Ages 6–11
GlaxoSmithKline · Sites in United States, United Kingdom
Ages 12+
By country, each count listing its studies:
Of the 416 Asthma studies recruiting now, 140 (34%) set no upper age limit and 204 (49%) stop at 75 or younger; 146 take children under 18; 105 take healthy volunteers.
This study: 18 Years to 45 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
262 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 63 · Phase 2 60 · Phase 3 61 · Phase 4 53
First in 1999; this study’s year is marked. 2 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 20 is below the median of 79 across 3,345 interventional studies indexed under Asthma.
Median enrollment 93 across the 238 interventional studies, 512 across the 24 observational. Of the 240 that completed or were terminated, 132 (55%) have results posted.
This tab as a report to print or save as PDF → With an account.
GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.
Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.
5 of the studies in Asthma by GlaxoSmithKline that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07645248Phase 3GlaxoSmithKlineA Study to Compare Safety of 4 Weeks Exposure to Propellants Hydrofluoroalkane 1,1-difluoroethane (HFA-152a) and HFA-1,1,1,2-tetrafluoroethane (134a) | 2026-12-28 |
| NCT05757102Phase 3GlaxoSmithKlineA Study to Compare the Efficacy, Safety and Tolerability of FF/UMEC/VI With FF/VI in 12-17-year-olds With Asthma | 2027-01-26 |
| NCT07671001Phase 3GlaxoSmithKlineA Study of Depemokimab in Participants of 6 to 11 Years of Age | 2027-03-01 |
| NCT07712393GlaxoSmithKlineA Comparative Study to Investigate the Difference in Blood Levels of Two Different Formulations of GSK5784283 | 2027-04-13 |
| NCT06433921GlaxoSmithKlineA Study to Compare the Relative Potency of Salbutamol Administered Via Metered Dose Inhalers (MDI) Containing Propellants HFA-152a to HFA-134a in Mild Asthmatics Aged 18 to 65 Inclusive | 2027-04-16 |
Add all 5 to your calendar (.ics) → With an account.
Among the 262 studies in Asthma by GlaxoSmithKline, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of the study is to assess the propellants,1 - Difluoroethane [HFA-152a] (Test) and 1,1,1,2-Tetrafluoroethane [HFA-134a] (Reference) for their potential to cause the airways to tighten when delivered through pressurized metered dose inhalers (pMDI). The rationale for this study is to develop a low carbon footprint alternative propellant, HFA-152a, which will have a lower impact on global warming.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Participants are eligible to be included in the study if all the following criteria apply:
Receiving 1 of the following asthma treatments, at a stable dose, for at least 12 weeks prior to the screening visit and is anticipated to remain stable for the duration of the study:
A female participant is eligible to participate if she is not pregnant or breastfeeding, and one of the following conditions applies:
Exclusion Criteria:
Participants are excluded from the study if any of the following criteria apply:
Stable doses (3 months or longer) of the following are permitted:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: HFA-152A propellant · Drug: HFA-134A propellant
Drug: HFA-152A propellant · Drug: HFA-134A propellant
HFA-152A propellant is administered via oral inhalation
HFA-134A propellant is administered via oral inhalation
Percentage Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) at 15 Minutes Post-dose
FEV1 is defined as the volume of air that can be forced out in one second, after taking a deep breath and measured using spirometry. Baseline is defined as the latest pre-dose assessment with a non-missing value including those from unscheduled visits.
Time frame: Baseline (Day 1, pre-dose) and at 15 minutes post-dose
Area Under the Curve for FEV1 From Time Zero to 15 Minutes (FEV1 AUC0-15 Mins)
FEV1 was measured using spirometry. AUC was assessed from the first non-missing timepoint to the 15 minute time point.
Time frame: Up to 15 minutes post-dose
Percentage Change From Baseline in FEV1 at 5, 60, and 180 Minutes Post-dose
FEV1 is defined as the volume of air that can be forced out in one second, after taking a deep breath and measured using spirometry. Baseline is defined as the latest pre-dose assessment with a non-missing value including those from unscheduled visits.
Time frame: Baseline (Day 1, pre-dose) and at 5, 60, and 180 minutes post-dose
Number of Participants With Percentage Change From Baseline in FEV1 <-15% at Timepoints 5, 15, 60 and 180 Minutes Post-dose
FEV1 is defined as the volume of air that can be forced out in one second, after taking a deep breath and using spirometry. Baseline is defined as the latest pre-dose assessment with a non-missing value including those from unscheduled visits.
Time frame: Baseline (Day 1, pre-dose) and at 5, 15, 60 and 180 minutes post-dose
Number of Participants With Adverse Events (AEs) and Serious AEs (SAEs)
An AE is defined as any untoward medical occurrence in a clinical study participant that was temporally associated with the use of a study intervention, regardless of whether it was related to the study intervention. An SAE is defined as any untoward medical occurrence that, at any dose, resulted in death, was life-threatening, required hospitalization or prolongation of existing hospitalization, resulted in disability or incapacity, or was a congenital anomaly, birth defect, or abnormal pregnancy outcome. SAEs are a subset of AEs. AEs were coded using the Medical Dictionary for Regulatory Activities (MedDRA) coding system.
Time frame: Up to approximately 85 days
| Milestone | Salbutamol HFA-152a (Test) Followed by Salbutamol HFA-134a (Reference) | Salbutamol HFA-134a (Reference) Followed by Salbutamol HFA-152a (Test) |
|---|---|---|
| Started | 9 | 11 |
| Completed | 8 | 11 |
| Not completed | 1 | 0 |
| Withdrew: Adverse event | 1 | 0 |
| Milestone | Salbutamol HFA-152a (Test) Followed by Salbutamol HFA-134a (Reference) | Salbutamol HFA-134a (Reference) Followed by Salbutamol HFA-152a (Test) |
|---|---|---|
| Started | 8 | 11 |
| Completed | 8 | 11 |
| Not completed | 0 | 0 |
FEV1 is defined as the volume of air that can be forced out in one second, after taking a deep breath and measured using spirometry. Baseline is defined as the latest pre-dose assessment with a non-missing value including those from unscheduled visits.
| Percentage change | Salbutamol HFA-152a (Test) | Salbutamol HFA-134a (Reference) |
|---|---|---|
| Percentage Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) at 15 Minutes Post-dose | -0.37 (-3.42 to 2.68) | -0.60 (-3.65 to 2.44) |
FEV1 was measured using spirometry. AUC was assessed from the first non-missing timepoint to the 15 minute time point.
| Liter*minutes (L*mins) | Salbutamol HFA-152a (Test) | Salbutamol HFA-134a (Reference) |
|---|---|---|
| Area Under the Curve for FEV1 From Time Zero to 15 Minutes (FEV1 AUC0-15 Mins) | 48.51 (43.83 to 53.18) | 49.56 (44.88 to 54.24) |
FEV1 is defined as the volume of air that can be forced out in one second, after taking a deep breath and measured using spirometry. Baseline is defined as the latest pre-dose assessment with a non-missing value including those from unscheduled visits.
| Percentage change | Salbutamol HFA-152a (Test) | Salbutamol HFA-134a (Reference) |
|---|---|---|
| Change from baseline (CFB) to 5 mins post-dose | 1.89 (-1.15 to 4.94) | 3.64 (0.59 to 6.69) |
| CFB to 60 mins post-dose | 0.56 (-2.49 to 3.61) | -0.30 (-3.35 to 2.75) |
| CFB to 180 mins post-dose | 2.82 (-0.23 to 5.86) | 0.24 (-2.81 to 3.29) |
FEV1 is defined as the volume of air that can be forced out in one second, after taking a deep breath and using spirometry. Baseline is defined as the latest pre-dose assessment with a non-missing value including those from unscheduled visits.
| Participants | Salbutamol HFA-152a (Test) | Salbutamol HFA-134a (Reference) |
|---|---|---|
| 5 mins post-dose | 0 | 0 |
| 15 mins post-dose | 0 | 1 |
| 60 mins post-dose | 0 | 1 |
| 180 mins post-dose | 0 | 0 |
An AE is defined as any untoward medical occurrence in a clinical study participant that was temporally associated with the use of a study intervention, regardless of whether it was related to the study intervention. An SAE is defined as any untoward medical occurrence that, at any dose, resulted in death, was life-threatening, required hospitalization or prolongation of existing hospitalization, resulted in disability or incapacity, or was a congenital anomaly, birth defect, or abnormal pregnancy outcome. SAEs are a subset of AEs. AEs were coded using the Medical Dictionary for Regulatory Activities (MedDRA) coding system.
| Participants | Salbutamol HFA-152a (Test) | Salbutamol HFA-134a (Reference) |
|---|---|---|
| AE | 1 | 1 |
| SAE | 0 | 0 |
Collected over All-cause mortality, non-SAEs and SAEs were collected up to approximately 85 days.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Salbutamol HFA-152a (Test) | 0/20 (0%) | 0/20 (0%) | 1/20 (5%) |
| Salbutamol HFA-134a (Reference) | 0/19 (0%) | 0/19 (0%) | 1/19 (5.3%) |
| Event | Salbutamol HFA-152a (Test) | Salbutamol HFA-134a (Reference) |
|---|---|---|
| RashSkin and subcutaneous tissue disorders | 0/20 | 1/19 |
| DiarrhoeaGastrointestinal disorders | 1/20 | 0/19 |
| UrticariaSkin and subcutaneous tissue disorders | 1/20 | 0/19 |
| Age, Continuous(years) | Salbutamol HFA-152a (Test) Followed by Salbutamol HFA-134a (Reference) | Salbutamol HFA-134a (Reference) Followed by Salbutamol HFA-152a (Test) | Total |
|---|---|---|---|
| Mean | 36.0 ± 8.66 | 30.0 ± 6.50 | 32.7 ± 7.95 |
| Sex: Female, Male(Participants) | Salbutamol HFA-152a (Test) Followed by Salbutamol HFA-134a (Reference) | Salbutamol HFA-134a (Reference) Followed by Salbutamol HFA-152a (Test) | Total |
|---|---|---|---|
| Female | 4 | 6 | 10 |
| Male | 5 | 5 | 10 |
| Race (NIH/OMB)(Participants) | Salbutamol HFA-152a (Test) Followed by Salbutamol HFA-134a (Reference) | Salbutamol HFA-134a (Reference) Followed by Salbutamol HFA-152a (Test) | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 1 | 1 | 2 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 5 | 4 | 9 |
| White | 2 | 6 | 8 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 1 | 0 | 1 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — GSK will assess requests from qualified researchers for anonymized individual patient-level data and related study documents. Data sharing is subject to certain criteria, conditions, and exceptions. For further information, refer to https://www.gsk-studyregister.com/About_GSK_Patient_Level_Data_Sharing_Final_13July2023.pdf
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Time frame: Anonymized IPD will be made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or asset(s) with development terminated across all indications.
Access criteria: Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months, but an extension may be granted, when justified, for up to 6 months.
Data sharing details ↗ · www.gsk-studyregister.com
Ran from Mar 2025 to primary completion in Jun 2025, 2 months.
Results were first posted in Aug 2026, 1 year 2 months after primary completion.
Of 173 industry-sponsored phase 1 interventional studies under Asthma, half reached primary completion within 6 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 12. This study's 2 months is below that.
Counting every sponsor, half of 200 studies reached it within 6 months; a quarter within 3 and three quarters within 14.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.